The AI-assisted early cancer screening system 'Cancernet-J,' developed by a research team at the University of Tokyo, has made a major breakthrough in clinical trials and is expected to usher in a new era of early cancer detection.

Technical Advantage: This system, based on deep learning, can simultaneously analyze 12 types of biomarkers, including ctDNA methylation in the blood and proteomic characteristics of circulating tumor cells. Such multi-omic integrated analysis has significantly improved the detection rate of early-stage cancer from the conventional 38% to 76%.

Future Applicability: As a non-invasive liquid biopsy approach, it avoids the discomfort and risks associated with endoscopic examinations. At the same time, the cost per test is planned to be kept under 8,000 yen, offering significant health economic advantages, and it is expected to become part of routine health check-ups in the future.

Progress and Certification: This system has obtained three types of medical device certifications from the Japanese Ministry of Health, Labour and Welfare as well as the EU CE certification, and is scheduled to begin clinical application in the spring of 2026, actively promoting internationalization.